Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Camptothecin
  • Carcinoma, Small Cell
  • Lung Neoplasms

abstract

  • Topotecan has significant activity in SCLC, particularly in patients sensitive to prior chemotherapy, with predictable and manageable toxicity. The incorporation of topotecan in combination chemotherapy regimens for future treatment of SCLC is warranted.

publication date

  • January 1997

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1200/JCO.1997.15.5.2090

PubMed ID

  • 9164222

Additional Document Info

start page

  • 2090

end page

  • 6

volume

  • 15

number

  • 5